WO2001025397A3 - Compositions and methods for tumor-targeted delivery of effector molecules - Google Patents
Compositions and methods for tumor-targeted delivery of effector molecules Download PDFInfo
- Publication number
- WO2001025397A3 WO2001025397A3 PCT/US2000/023242 US0023242W WO0125397A3 WO 2001025397 A3 WO2001025397 A3 WO 2001025397A3 US 0023242 W US0023242 W US 0023242W WO 0125397 A3 WO0125397 A3 WO 0125397A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- methods
- effector molecule
- effector molecules
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002386465A CA2386465A1 (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
AU69334/00A AU783714B2 (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
IL14893300A IL148933A0 (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
JP2001528552A JP2004500042A (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
KR1020027004371A KR20020059605A (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
MXPA02003384A MXPA02003384A (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules. |
NZ518354A NZ518354A (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
BR0014491-6A BR0014491A (en) | 1999-10-04 | 2000-08-24 | Tumor-marked attenuated bacteria, pharmaceutical composition, use of attenuated bacteria, and fusion protein |
EP00957764A EP1261369A4 (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15758199P | 1999-10-04 | 1999-10-04 | |
US15750099P | 1999-10-04 | 1999-10-04 | |
US15763799P | 1999-10-04 | 1999-10-04 | |
US60/157,500 | 1999-10-04 | ||
US60/157,581 | 1999-10-04 | ||
US60/157,637 | 1999-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001025397A2 WO2001025397A2 (en) | 2001-04-12 |
WO2001025397A3 true WO2001025397A3 (en) | 2002-01-24 |
Family
ID=27388022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/023242 WO2001025397A2 (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1261369A4 (en) |
JP (1) | JP2004500042A (en) |
KR (1) | KR20020059605A (en) |
CN (1) | CN1420783A (en) |
AU (1) | AU783714B2 (en) |
BR (1) | BR0014491A (en) |
CA (1) | CA2386465A1 (en) |
IL (1) | IL148933A0 (en) |
MX (1) | MXPA02003384A (en) |
NZ (1) | NZ518354A (en) |
WO (1) | WO2001025397A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9365625B1 (en) | 2011-03-31 | 2016-06-14 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
US9492534B2 (en) | 2003-06-18 | 2016-11-15 | Genelux Corporation | Microorganisms for therapy |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL134936A0 (en) | 1997-09-10 | 2001-05-20 | Vion Pharmaceuticals Inc | Genetically modified tumor-targeted bacteria with reduced virulence |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
AU2003219730A1 (en) | 2002-02-07 | 2003-09-02 | Massachusetts Institute Of Technology | Anti-pathogen treatements |
CA2513251C (en) | 2003-01-14 | 2013-03-19 | Dana-Farber Cancer Institute | Cancer therapy sensitizer |
WO2005012363A1 (en) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | Targeting inflammation inducer |
CN100435850C (en) * | 2004-03-22 | 2008-11-26 | 中国医学科学院血液学研究所 | Combination of medication produced from attenuated salmonella bacteria possessing effect of radiation protection and anti tumour |
US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
JP2008504822A (en) * | 2004-06-29 | 2008-02-21 | アンチキャンサー インコーポレーテッド | Cancer selective auxotrophic strain |
ITRM20050422A1 (en) * | 2005-08-05 | 2007-02-06 | Consiglio Nazionale Ricerche | PROTEIN FACTORS DERMONECROTIZZANTI OF BACTERIAL ORIGIN AND RELATED USES IN MEDICAL FIELD. |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
WO2009126189A1 (en) | 2008-01-11 | 2009-10-15 | Genelux Corporation | Methods and compositions for detection of bacteria and treatment of diseases and disorders |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
FR2960001A1 (en) * | 2010-05-12 | 2011-11-18 | Univ Rennes | RECOMBINANT VECTOR FOR THE PRODUCTION AND SECRETION OF AMINO ACID SEQUENCES OF INTEREST BY PROPIONIC BACTERIA AND ITS APPLICATIONS |
CN102604949A (en) * | 2011-04-12 | 2012-07-25 | 南京大学 | Anaerobic tissue selective gene expression method driven by alcohol dehydrogenase promoter and application thereof |
WO2013128288A1 (en) * | 2012-02-27 | 2013-09-06 | Thelial Technologies S.A. | Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics |
CN102731658B (en) * | 2012-05-15 | 2014-07-30 | 山东大学 | Tat PTD-Endostatin recombination protein, preparation method and application thereof |
TWI664976B (en) * | 2013-01-02 | 2019-07-11 | 美商迪科生物系統公司 | Compositions and methods for treatment of cancer using bacteria |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
EP2829274A1 (en) | 2013-07-25 | 2015-01-28 | Institut National De La Recherche Agronomique | Vectors for producing and secreting substance of interest by bacteria and applications thereof |
US10987432B2 (en) * | 2013-09-05 | 2021-04-27 | The University Of Hong Kong | Therapeutic delivery and expression system, methods and uses thereof |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
KR101685034B1 (en) * | 2015-04-10 | 2016-12-09 | 전남대학교 산학협력단 | Solid cancer tissue targeting bacterium and use thereof |
US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
CN107537027A (en) * | 2016-06-23 | 2018-01-05 | 南开大学 | TNFSF15 albumen is preparing the purposes in treating melanoma medicine |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
WO2018129404A1 (en) * | 2017-01-06 | 2018-07-12 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
CN107115533A (en) * | 2017-04-01 | 2017-09-01 | 广州华津医药科技有限公司 | Applications of the genetic engineering bacterium VNP20009 M in treatment malignant sarcomas medicine is prepared |
US20200149053A1 (en) * | 2017-07-12 | 2020-05-14 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
MY195280A (en) | 2017-09-08 | 2023-01-12 | New Portal Ltd | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability |
CN108314741B (en) * | 2018-03-22 | 2021-08-03 | 中国人民解放军第四军医大学 | Tumor blood vessel targeted anti-cancer peptide NKL-DOTA and preparation method thereof |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
CN110423772B (en) * | 2019-07-17 | 2023-04-21 | 上海科技大学 | Cytosine base editing plasmid for Acinetobacter baumannii and application of cytosine base editing plasmid |
US20230212270A1 (en) * | 2020-03-06 | 2023-07-06 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Serum albumin binding nanobody compositions and methods for using the same |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN114438111B (en) * | 2020-11-05 | 2023-08-11 | 深圳先进技术研究院 | Construction of PP2 strict anaerobic salmonella strain and application thereof in tumor treatment |
WO2023041809A1 (en) * | 2021-09-20 | 2023-03-23 | Pulmobiotics, S.L. | Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms |
CN116676324B (en) * | 2023-07-28 | 2023-10-27 | 四川大学华西医院 | System and method for constructing and releasing anti-tumor effector protein based on Kil protein |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040238A1 (en) * | 1995-06-07 | 1996-12-19 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0338679A3 (en) * | 1988-03-24 | 1991-03-06 | Genentech, Inc. | Tumour necrosis factor in the treatment of bladder cancer |
JP2000500734A (en) * | 1995-09-06 | 2000-01-25 | アメリカ合衆国 | Bacterial delivery system |
IL134936A0 (en) * | 1997-09-10 | 2001-05-20 | Vion Pharmaceuticals Inc | Genetically modified tumor-targeted bacteria with reduced virulence |
-
2000
- 2000-08-24 KR KR1020027004371A patent/KR20020059605A/en not_active Application Discontinuation
- 2000-08-24 CA CA002386465A patent/CA2386465A1/en not_active Abandoned
- 2000-08-24 WO PCT/US2000/023242 patent/WO2001025397A2/en active IP Right Grant
- 2000-08-24 IL IL14893300A patent/IL148933A0/en unknown
- 2000-08-24 AU AU69334/00A patent/AU783714B2/en not_active Ceased
- 2000-08-24 MX MXPA02003384A patent/MXPA02003384A/en unknown
- 2000-08-24 EP EP00957764A patent/EP1261369A4/en not_active Withdrawn
- 2000-08-24 NZ NZ518354A patent/NZ518354A/en unknown
- 2000-08-24 BR BR0014491-6A patent/BR0014491A/en not_active Application Discontinuation
- 2000-08-24 JP JP2001528552A patent/JP2004500042A/en active Pending
- 2000-08-24 CN CN00816714A patent/CN1420783A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040238A1 (en) * | 1995-06-07 | 1996-12-19 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
Non-Patent Citations (4)
Title |
---|
CHEN ET AL.: "Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice", CANCER RES., vol. 59, no. 14, July 1999 (1999-07-01), pages 3308 - 3312, XP000857407 * |
LOW ET AL.: "Lipid A mutant salmonella with suppressed virulence and TNFa induction retain tumor-targeting in vivo", NATURE BIOTECHNOLOGY, vol. 17, January 1999 (1999-01-01), pages 37 - 41, XP002939412 * |
MARR ET AL.: "Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha", GENE THER., vol. 4, no. 11, November 1997 (1997-11-01), pages 1181 - 1188, XP000914782 * |
PAWELEK ET AL.: "Tumor targeted salmonella as a novel anticancer vector", CANCER RESEARCH, vol. 57, October 1997 (1997-10-01), pages 4537 - 4544, XP002939411 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492534B2 (en) | 2003-06-18 | 2016-11-15 | Genelux Corporation | Microorganisms for therapy |
US9365625B1 (en) | 2011-03-31 | 2016-06-14 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
Also Published As
Publication number | Publication date |
---|---|
MXPA02003384A (en) | 2002-08-20 |
BR0014491A (en) | 2004-03-09 |
AU783714B2 (en) | 2005-12-01 |
JP2004500042A (en) | 2004-01-08 |
KR20020059605A (en) | 2002-07-13 |
WO2001025397A2 (en) | 2001-04-12 |
AU6933400A (en) | 2001-05-10 |
EP1261369A2 (en) | 2002-12-04 |
CN1420783A (en) | 2003-05-28 |
CA2386465A1 (en) | 2001-04-12 |
NZ518354A (en) | 2005-02-25 |
EP1261369A4 (en) | 2006-02-01 |
IL148933A0 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001025397A3 (en) | Compositions and methods for tumor-targeted delivery of effector molecules | |
AU2002359122A1 (en) | Novel compounds | |
WO2002002077A3 (en) | Liposomal antineoplastic drugs and uses thereof | |
CA2292359A1 (en) | Novel azalides and methods of making same | |
CA2129288A1 (en) | Phosphonooxymethyl Esters of Taxane Derivatives | |
EP1181013A4 (en) | Method and composition for the treatment of cancer | |
DE60116761D1 (en) | Adamantanderivate | |
CA2343236A1 (en) | 4,4-biarylpiperidine derivatives | |
AU2003274823A1 (en) | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy | |
AU6272598A (en) | Highly lipophilic camptothecin derivatives | |
WO2000066093A3 (en) | Combined preparations comprising morpholine anthracyclines and anticancer agent | |
EP1392328A4 (en) | Cancer therapy | |
ZA200500908B (en) | Ruthenium anticancer complexes | |
IL137964A0 (en) | Antitumor agents | |
AU6369900A (en) | Aromatic esters of camptothecins and methods to treat cancers | |
PL313078A1 (en) | Novel bis-naphtalimides for use in treating carcinoma | |
CA2385996A1 (en) | Anticancer agents | |
AU5705099A (en) | Compounds useful as aicarft inhibitors | |
AUPR118000A0 (en) | Therapeutic molecules and methods | |
CA2095352A1 (en) | Compositions containing psyllium | |
AU2003213661A1 (en) | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | |
AU2001296677A1 (en) | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | |
AU2001267687A1 (en) | Ruthenium (ii) compounds for use in the therapy of cancer | |
AU2002249103A1 (en) | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors | |
YU46302A (en) | Substituted pyrroles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 148933 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2386465 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/003384 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 528552 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027004371 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 69334/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 518354 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000957764 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008167141 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027004371 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000957764 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 518354 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 518354 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 69334/00 Country of ref document: AU |